Physician
Oncology
Dr. Howard L. Parnes, MD
|
|
Give Review
Howard Parnes practices Oncology. He studied medicine at Rutgers New Jersey Medical School. Rutgers New Jersey Medical School is ranked 76 in research and 0 in primary care medicine Howard L. Parnes, MD is a published doctor and has 50 publications published. The lastest was: 'Effect of Finasteride on Serum Androstenedione and Risk of Prostate Cancer Within the Prostate Cancer Prevention Trial: Differential Effect on High- and Low-grade Dise...'
Publications
- Effect of Finasteride on Serum Androstenedione and Risk of Prostate Cancer Within the Prostate Cancer Prevention Trial: Differential Effect on High- and Low-grade Dise...
- Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.
- Cutaneous Adverse Effects Associated With the Tyrosine-Kinase Inhibitor Cabozantinib.
- Plasma Tocopherols and Risk of Prostate Cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
- Addressing overdiagnosis and overtreatment in cancer: a prescription for change.
- Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer.
- Statin Drug Use Is Not Associated with Prostate Cancer Risk in Men who are Regularly Screened.
- Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial.
- Long-term survival of participants in the prostate cancer prevention trial.
- Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer.
- Prostate cancer prevention: strategies for agent development.
- Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.
- Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial.
- Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity.
- Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials.
- Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study.
- Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.
- Transition of a clinical trial into translational research: the prostate cancer prevention trial experience.
- A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.
- BCAN Think Tank session 3: Prevention of bladder cancer.
- Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
- Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
- Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.
- Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.
- A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
- Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
- Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.
- Does the level of prostate cancer risk affect cancer prevention with finasteride?
- Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment.
- Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer.
- Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research.
- Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
- Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
- Finasteride decreases the risk of prostatic intraepithelial neoplasia.
- Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
- Early treatment gets the benefit.
- Chemoprevention in prostate cancer.
- Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
- Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.
- A phase II study of perifosine in androgen independent prostate cancer.
- Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
- Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
- Prevention of hormone-related cancers: prostate cancer.
- Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
- Science peels the onion of selenium effects on prostate carcinogenesis.
- First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement.
- Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio.
- Phase III Prostate Cancer Chemoprevention Trials.
- Prostate cancer prevention: agent development strategies.
Schools
University of Medicine And Dentistry of New Jersey Newark
Baltimore City Hosps
University MD Canc Ctrs
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Maryland -
Johns Hopkins Bayview Medical Center -
Rutgers New Jersey Medical School
Helpful Reviews
Similar Doctors
|
|
Dr. Joanne Zujewski, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Norman Coleman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert L. Ramsey, MD |
|
|
Dr. Geoffrey S. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher S. Hourigan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carolyn B. Hendricks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jaye L. Viner, MD
This Doctor is OpenDoctor Recommended.
|